Deferred GP IIb/IIIa inhibitors reduced the 30-day rates of major bleeding compared with Similar results were reported by the EARLYACS investigators, who evaluated eptifibatide given upstream versus delayed, provisional admin- istration in >9000 patients with NSTE-ACS.295 The compos- ite endpoint of death, MI, recurrent ischemia requiring urgent revascularization, or thrombotic complications occurred in 9.3% of patients in the early-eptifibatide group compared with 10% in the delayed-eptifibatide group (odds ratio [OR]: 0.92; As in the ACUITY Timing trial, the early-eptifibatide group had significantly higher rates of bleeding and red cell transfusions.295,308 Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e367 4.3.2. Initial Parenteral Anticoagulant Therapy in Patients With Definite NSTE-ACS: Recommendations See Table 7 for a summary of recommendations regarding antiplatelet/anticoagulant therapy in patients with definite or likely NSTE-ACS and Online Data Supplement 16 for addi- tional information on combined oral anticoagulant therapy and antiplatelet therapy in patients with definite NSTE-ACS. Class I 1. In patients with NSTE-ACS, anticoagulation, in ad- dition to antiplatelet therapy, is recommended for all patients irrespective of initial treatment strategy. Treatment options include: Enoxaparin: 1 mg/kg subcutaneous (SC) every 12 hours (reduce dose to 1 mg/kg SC once daily in patients with creatinine clearance [CrCl] <30 mL/min), continued for the duration of hos- pitalization or until PCI is performed. 